PHATHOM PHARMACEUTICALS, INC. Interest Expense
PHATHOM PHARMACEUTICALS, INC. (PHAT) reported Interest Expense of $17.76 million for the 3-month period ending 2024-06-30, per its 10-Q filed 2024-08-08.
Discontinued › Expense Statement › Interest Expense
us-gaap:InterestExpense · last filed 2024-08-08
- PHATHOM PHARMACEUTICALS, INC. interest expense for the quarter ending 2024-06-30 was $17.76M, a 84.75% increase year-over-year.
- PHATHOM PHARMACEUTICALS, INC. interest expense for the quarter ending 2024-03-31 was $17.17M, a 86.26% increase year-over-year.
- PHATHOM PHARMACEUTICALS, INC. interest expense for the quarter ending 2023-12-31 was $13.03M, a 35.69% increase year-over-year.
- PHATHOM PHARMACEUTICALS, INC. interest expense for the quarter ending 2023-09-30 was $10.11M, a 8.95% increase year-over-year.
- PHATHOM PHARMACEUTICALS, INC. interest expense for fiscal 2023 was $41.97M, a 53.70% increase from fiscal 2022.
- PHATHOM PHARMACEUTICALS, INC. interest expense for fiscal 2022 was $27.30M, a 302.25% increase from fiscal 2021.
- PHATHOM PHARMACEUTICALS, INC. interest expense for fiscal 2021 was $6.79M, a 48.18% increase from fiscal 2020.
- PHATHOM PHARMACEUTICALS, INC. interest expense for fiscal 2020 was $4.58M, a 9.67% increase from fiscal 2019.
| Period end | Interest Expense 3 month | Interest Expense 6 month | Interest Expense 9 month | Interest Expense 12 month |
|---|---|---|---|---|
| 2024-06-30 | $17.76M 10-Q · filed 2024-08-08 | $34.93M 10-Q · filed 2024-08-08 | $47.96M derived: sum of 3 quarters · filed 2024-08-08 | $58.07M derived: sum of 4 quarters · filed 2024-08-08 |
| 2024-03-31 | $17.17M 10-Q/A · filed 2024-06-14 | $30.20M derived: sum of 2 quarters · filed 2024-06-14 | $40.30M derived: sum of 3 quarters · filed 2024-06-14 | $49.92M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-12-31 | $13.03M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-06-14 | $23.14M derived: sum of 2 quarters · filed 2024-06-14 | $32.75M derived: sum of 3 quarters · filed 2024-08-08 | $41.97M 10-K/A · filed 2024-06-14 |
| 2023-09-30 | $10.11M 10-Q · filed 2023-11-09 | $19.72M derived: sum of 2 quarters · filed 2024-08-08 | $28.94M 10-Q · filed 2023-11-09 | $38.54M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-06-30 | $9.62M 10-Q · filed 2024-08-08 | $18.83M 10-Q · filed 2024-08-08 | $28.43M derived: sum of 3 quarters · filed 2024-08-08 | $37.71M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $9.22M 10-Q/A · filed 2024-06-14 | $18.82M derived: sum of 2 quarters · filed 2024-06-14 | $28.10M derived: sum of 3 quarters · filed 2024-06-14 | $33.76M derived: sum of 4 quarters · filed 2024-06-14 |
| 2022-12-31 | $9.60M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-06-14 | $18.88M derived: sum of 2 quarters · filed 2024-06-14 | $24.55M derived: sum of 3 quarters · filed 2024-06-14 | $27.30M 10-K/A · filed 2024-06-14 |
| 2022-09-30 | $9.28M 10-Q · filed 2023-11-09 | $14.94M derived: sum of 2 quarters · filed 2023-11-09 | $17.70M 10-Q · filed 2023-11-09 | $20.48M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $5.67M 10-Q · filed 2023-08-10 | $8.43M 10-Q · filed 2023-08-10 | $11.20M derived: sum of 3 quarters · filed 2023-08-10 | $12.69M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $2.76M 10-Q · filed 2023-05-10 | $5.53M derived: sum of 2 quarters · filed 2023-05-10 | $7.02M derived: sum of 3 quarters · filed 2023-05-10 | $8.28M derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | $2.77M derived: 10-K 12 month − 10-Q/A 9 month · filed 2023-02-28 | $4.26M derived: sum of 2 quarters · filed 2023-02-28 | $5.52M derived: sum of 3 quarters · filed 2023-02-28 | $6.79M 10-K · filed 2023-02-28 |
| 2021-09-30 | $1.49M 10-Q/A · filed 2022-11-09 | $2.74M derived: sum of 2 quarters · filed 2022-11-09 | $4.01M 10-Q/A · filed 2022-11-09 | $5.31M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $1.26M 10-Q · filed 2022-08-02 | $2.53M 10-Q · filed 2022-08-02 | $3.82M derived: sum of 3 quarters · filed 2022-08-02 | $5.11M derived: sum of 4 quarters · filed 2022-08-02 |
| 2021-03-31 | $1.27M 10-Q · filed 2022-05-10 | $2.57M derived: sum of 2 quarters · filed 2022-05-10 | $3.85M derived: sum of 3 quarters · filed 2022-05-10 | $5.12M derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | $1.29M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $2.58M derived: sum of 2 quarters · filed 2022-03-01 | $3.84M derived: sum of 3 quarters · filed 2022-03-01 | $4.58M 10-K · filed 2022-03-01 |
| 2020-09-30 | $1.29M 10-Q · filed 2021-11-08 | $2.55M derived: sum of 2 quarters · filed 2021-11-08 | $3.29M 10-Q · filed 2021-11-08 | $4.33M derived: sum of 4 quarters · filed 2021-11-08 |
| 2020-06-30 | $1.26M 10-Q · filed 2021-08-10 | $2.00M 10-Q · filed 2021-08-10 | $3.04M derived: sum of 3 quarters · filed 2021-08-10 | $5.03M derived: sum of 4 quarters · filed 2021-08-10 |
| 2020-03-31 | $738.00K 10-Q · filed 2021-05-11 | $1.78M derived: sum of 2 quarters · filed 2021-05-11 | $3.77M derived: sum of 3 quarters · filed 2021-05-11 | $4.90M derived: sum of 4 quarters · filed 2021-05-11 |
| 2019-12-31 | $1.04M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-30 | $3.03M derived: sum of 2 quarters · filed 2021-03-30 | $4.17M derived: sum of 3 quarters · filed 2021-03-30 | $4.18M 10-K · filed 2021-03-30 |
| 2019-09-30 | $1.99M 10-Q · filed 2020-11-10 | $3.13M derived: sum of 2 quarters · filed 2020-11-10 | $3.14M 10-Q · filed 2020-11-10 | $3.14M derived: sum of 4 quarters · filed 2020-11-10 |
| 2019-06-30 | $1.14M 10-Q · filed 2020-08-06 | $1.15M 10-Q · filed 2020-08-06 | $1.15M derived: sum of 3 quarters · filed 2020-08-06 | $1.16M derived: sum of 4 quarters · filed 2020-08-06 |
| 2019-03-31 | $11.00K 10-Q · filed 2020-05-12 | $16.00K derived: sum of 2 quarters · filed 2020-05-12 | $20.00K derived: sum of 3 quarters · filed 2020-05-12 | |
| 2018-12-31 | $5.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-19 | $9.00K derived: sum of 2 quarters · filed 2020-03-19 | $13.00K 10-K · filed 2020-03-19 | |
| 2018-09-30 | $4.00K 10-Q · filed 2019-11-25 | $8.00K 10-Q · filed 2019-11-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 |